ABVC - CIK 0001173313
ABVC BIOPHARMA, INC. trades as ABVC. In its fiscal 2025 annual report the company posted revenue of $296.00K, down 41.9% from the prior year and net income of -$7.91M. This page tracks ABVC BIOPHARMA, INC. through 780 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -87184.2% to -2671.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-18 |
| NT 10-Q | - | 2026-05-15 |
| POS AM | - | 2026-03-27 |
| Major company event | 8-K | 2026-03-27 |
| Proxy statement | DEF 14A | 2026-03-05 |
| Annual report | 10-K | 2026-03-03 |
| Quarterly report (amended) | 10-Q/A | 2026-03-03 |
| Major company event | 8-K | 2026-03-03 |
The largest companies sharing ABVC BIOPHARMA, INC.'s SEC industry classification (pharmaceutical preparations).
ABVC BIOPHARMA, INC. reported revenue of $296.00K for fiscal year 2025, a decrease of 41.9% year over year.
In its latest fiscal year ABVC BIOPHARMA, INC. reported a net loss of $7.91M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.